With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic

One month after approving the first CAR T-cell therapy for cancer, FDA has approved a second such therapy. The treatment, axicabtagene ciloleucel (Yescarta™), was approved for some patients with advanced non-Hodgkin lymphoma.

Cancer Currents: An NCI Cancer Research Blog